Smoking-Cessation and Stimulant Treatment (S-CAST)

Phase 3

Completed

Conditions: Cocaine Dependence
Methamphetamine Dependence
Nicotine Dependence

Brief Summary: The primary objective of this study is to evaluate the impact of substance-abuse treatment as usual plus smoking-cessation treatment (TAU+SCT), relative to substance-abuse treatment as usual (TAU), on drug-abuse outcomes. Specifically, this study will evaluate whether concurrent smoking-cessation treatment improves, worsens, or has no effect on stimulant-use outcomes in smokers who are in outpatient substance-abuse treatment for cocaine or methamphetamine dependence.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Clinical diagnosis of current alcohol or sedative dependence, bipolar disorder; or a life-time diagnosis of anorexia nervosa or bulimia
Seeking/receiving treatment for opiate-agonist replacement therapy
Medical conditions that could compromise participant safety
Taking medications with known/potential interactions with bupropion
Hypersensitivity to bupropion, nicotine, or menthol
Pregnant or breastfeeding
Abnormal ECG
Recent smoking cessation treatment
Use of tobacco products other than cigarettes in the past week
Likely to enter residential/inpatient treatment within 10 weeks
Have all stimulant-positive urine drug screens during screening/baseline

Primary Outcome Measures

Name	Time	Method
Stimulant-free Weeks Assessed by Self-report and Twice-weekly Urine Drug Screens	Week 16	Stimulant-free week results (no cocaine, methamphetamine and amphetamine use) were obtained by combining the urine drug screens (UDS) and the self-reported Timeline Follow-Back (TLFB). At the group level, this outcome translates into the percentage of weeks in each study arm that are stimulant-free.

Secondary Outcome Measures

Name	Time	Method
Stimulant-free Results at 6-month Visit	6 - months follow-up visit	At the 6-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back.
Point-prevalence Abstinence (Smoking Outcome)	Week 10 assessment	point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm
Four Week Continuous Smoking Abstinence	Post-quit days 15-42	A combination of daily self-reported smoking data and weekly carbon monoxide levels were used to determine continuous abstinence during post-quit days 15 - 42.
Stimulant-free Results at 3-month Visit	3-month follow-up visit	At the 3-month follow-up visit, percentage of participants with a negative urine drug screen for stimulant use and no stimulant use days reported during the past 28 days based on Timeline Follow-back.
Point-prevalence Abstinence (Smoking Outcome) 3 Month Visit	3- month follow-up visits	point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm
Point-prevalence Abstinence (Smoking Outcome) 6 Month Visit	6 month visit	point-prevalence abstinence defined as not smoking in the previous seven days based on self-report and confirmed with a Carbon Monoxide (CO) level ≤ 8 ppm

Locations (12): La Frontera
🇺🇸
Tucson, Arizona, United States
Matrix Institute on Addictions
🇺🇸
Rancho Cucamonga, California, United States
Tarzana Treatment Centers
🇺🇸
Tarzana, California, United States
Gateway
🇺🇸
Jacksonville, Florida, United States
Gibson Recovery Center, Inc.
🇺🇸
Cape Girardeau, Missouri, United States
Maryhaven
🇺🇸
Columbus, Ohio, United States
ADAPT
🇺🇸
Roseburg, Oregon, United States
Addiction Medicine Services
🇺🇸
Pittsburgh, Pennsylvania, United States
Lexington/Richland Alcohol and Drug Abuse Council
🇺🇸
Columbia, South Carolina, United States
Behavioral Health Services of Pickens County
🇺🇸
Pickens, South Carolina, United States
Scroll for more (2 remaining)
La Frontera
🇺🇸Tucson, Arizona, United States